Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hofland, L. J.
Right arrow Articles by Lamberts, S. W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hofland, L. J.
Right arrow Articles by Lamberts, S. W. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:S31-S36, 2001
© 2001 European Society for Medical Oncology

Reviews

Somatostatin receptor subtype expression in human tumors

L. J. Hofland and S. W. J. Lamberts

Department of Internal Medicine, Erasmus University Medical Centre Rotterdam (EMCR) Rotterdam, The Netherlands

Correspondence to: Dr L. J. Hofland Department of Internal Medicine, Room Bd277, University Hospital Dijkzigt Dr Molewaterplein 40 3015 GD Rotterdam, The Netherlands E-mail: hofland{at}inw3.azr.nl

The presence of functional SSR in tumors has several clinical implications which include the possibility a) to control hormonal hypersecretion and related symptomatology by treatment with SS-analogs, b) to detect SSR positive tumors and their metastases by in vivo SSR scintigraphy, and c) to carry out SSR-targeted radiotherapy using radiolabeled SS-analogs. The majority of SSR positive tumors show a differential expression of somatostatin receptor subtypes, sst2 receptors being the most frequently expressed SSR subtype. The predominant expression of sst2 receptors forms the basis for the successful application of sst preferring agonists in the treatment of patients with GH-secreting pituitary adenomas, as well as in patients with carcinoid or islet cell tumors. Sst2 and sst5 receptors appear to be differentially involved in the regulation of normal and tumoral pituitary hormone secretion. Additionally, sst2 receptors are involved in the receptor-mediated internalisation of sst2 preferring radiolabeled SS-analogs. The predominant expression of sst2 receptors in neuroendocrine tumors probably determines the successful application of radio-labeled SS-analogs for the detection of primary tumors and their metastases by SSR scintigraphy.

In conclusion, the efficacy of treatment with SS-analogs, the visualisation of SSR-positive tumors, as well as the possibility to carry out SSR-targeted radiotherapy, may very well depend upon the density and subtype of SSR that is expressed by the tumors. Therefore, the characterisation of SSR subtypes in human tumors may have important clinical consequences.

hormone secretion, receptor, somatostatin, targeted radiotherapy, tumor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Mol EndocrinolHome page
D. Ferone, F. Gatto, M. Arvigo, E. Resmini, M. Boschetti, C. Teti, D. Esposito, and F. Minuto
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology
J. Mol. Endocrinol., May 1, 2009; 42(5): 361 - 370.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. Colao, C. Di Somma, R. Pivonello, A. Faggiano, G. Lombardi, and S. Savastano
Medical therapy for clinically non-functioning pituitary adenomas
Endocr. Relat. Cancer, December 1, 2008; 15(4): 905 - 915.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Colao, M. Filippella, R. Pivonello, C. Di Somma, A. Faggiano, and G. Lombardi
Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours
Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S57 - S63.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
M C Zatelli, D Piccin, F Tagliati, A Bottoni, M R Ambrosio, A Margutti, M Scanarini, M Bondanelli, M D Culler, and E C d. Uberti
Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro
J. Mol. Endocrinol., October 1, 2005; 35(2): 333 - 341.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
V. A.S.H. Dalm, L. J. Hofland, C. M. Mooy, M. A. Waaijers, P. M. van Koetsveld, A. W. Langerak, F. T.J. Staal, A.-J. van der Lely, S. W.J. Lamberts, and M. P. van Hagen
Somatostatin Receptors in Malignant Lymphomas: Targets for Radiotherapy?
J. Nucl. Med., January 1, 2004; 45(1): 8 - 16.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.